Sophiris Bio

United States
San Diego, California, United States, 92037

Company profile

Sophiris Bio company profile

Sophiris Bio is a biotech company that develops a treatment for the symptoms of benign prostatic hyperplasia. Their product includes topsalysin for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia and for the treatment of low- to intermediate-risk prostate cancer.

Business identity

Contact email
[email protected]
Phone number
+1 858 777 1760
Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2002-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$37.2M
Last funding
Post IPO Debt / $10M / 2017-09-14
Last equity funding
Post IPO Equity / $2M
Investors
4
Lead investors
3
Founders
1
Articles
14
Closed on
2020-09-10
Exited on
2013-08-16

Founders and investors

Founders

Thomas Buckley

Lead investors

Aspire Capital Partners LLCSilicon Valley BankWarburg Pincus

Investors

Aspire Capital Partners LLCSilicon Valley BankSofinnova InvestmentsWarburg Pincus